With respiratory illnesses ravaging children around the US, vaccine partners Pfizer and BioNTech announced Monday that they are seeking regulatory authorization to offer their bivalent COVID-19 vaccine to children ages 6 months to 4 years-but not as a booster; instead it would be part of an updated primary series.
[
add
]
[
|
|
...
]